252 related articles for article (PubMed ID: 25896974)
1. Clinically Relevant Molecular Subtypes in Leiomyosarcoma.
Guo X; Jo VY; Mills AM; Zhu SX; Lee CH; Espinosa I; Nucci MR; Varma S; Forgó E; Hastie T; Anderson S; Ganjoo K; Beck AH; West RB; Fletcher CD; van de Rijn M
Clin Cancer Res; 2015 Aug; 21(15):3501-11. PubMed ID: 25896974
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtyping of leiomyosarcoma with 3' end RNA sequencing.
Guo X; Forgó E; van de Rijn M
Genom Data; 2015 Sep; 5():366-367. PubMed ID: 26240788
[TBL] [Abstract][Full Text] [Related]
3. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.
An Y; Wang S; Li S; Zhang L; Wang D; Wang H; Zhu S; Zhu W; Li Y; Chen W; Ji S; Guo X
BMC Cancer; 2017 Sep; 17(1):639. PubMed ID: 28893210
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling identifies distinct molecular subgroups of leiomyosarcoma with clinical relevance.
Lee YF; Roe T; Mangham DC; Fisher C; Grimer RJ; Judson I
Br J Cancer; 2016 Oct; 115(8):1000-1007. PubMed ID: 27607470
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
[TBL] [Abstract][Full Text] [Related]
6. Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics.
Italiano A; Lagarde P; Brulard C; Terrier P; Laë M; Marques B; Ranchere-Vince D; Michels JJ; Trassard M; Cioffi A; Piperno-Neumann S; Chevreau C; Blay JY; Delcambre C; Isambert N; Penel N; Bay JO; Bonvalot S; Le Cesne A; Coindre JM; Chibon F
Clin Cancer Res; 2013 Mar; 19(5):1190-6. PubMed ID: 23329812
[TBL] [Abstract][Full Text] [Related]
7. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract][Full Text] [Related]
8. Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome.
Barlin JN; Zhou QC; Leitao MM; Bisogna M; Olvera N; Shih KK; Jacobsen A; Schultz N; Tap WD; Hensley ML; Schwartz GK; Boyd J; Qin LX; Levine DA
Neoplasia; 2015 Feb; 17(2):183-9. PubMed ID: 25748237
[TBL] [Abstract][Full Text] [Related]
9. Tumor specific gene expression profiles in human leiomyosarcoma: an evaluation of intratumor heterogeneity.
Shmulevich I; Hunt K; El-Naggar A; Taylor E; Ramdas L; Labordé P; Hess KR; Pollock R; Zhang W
Cancer; 2002 Apr; 94(7):2069-75. PubMed ID: 11932911
[TBL] [Abstract][Full Text] [Related]
10. Differential gene expression in leiomyosarcoma.
Skubitz KM; Skubitz AP
Cancer; 2003 Sep; 98(5):1029-38. PubMed ID: 12942572
[TBL] [Abstract][Full Text] [Related]
11. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
12. Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas.
Chinyengetere F; Sekula DJ; Lu Y; Giustini AJ; Sanglikar A; Kawakami M; Ma T; Burkett SS; Eisenberg BL; Wells WA; Hoopes PJ; Demicco EG; Lazar AJ; Torres KE; Memoli V; Freemantle SJ; Dmitrovsky E
BMC Cancer; 2015 Nov; 15():886. PubMed ID: 26555296
[TBL] [Abstract][Full Text] [Related]
13. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
14. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.
Beck AH; Lee CH; Witten DM; Gleason BC; Edris B; Espinosa I; Zhu S; Li R; Montgomery KD; Marinelli RJ; Tibshirani R; Hastie T; Jablons DM; Rubin BP; Fletcher CD; West RB; van de Rijn M
Oncogene; 2010 Feb; 29(6):845-54. PubMed ID: 19901961
[TBL] [Abstract][Full Text] [Related]
15. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
16. Identifying molecular subtypes in human colon cancer using gene expression and DNA methylation microarray data.
Ren Z; Wang W; Li J
Int J Oncol; 2016 Feb; 48(2):690-702. PubMed ID: 26647925
[TBL] [Abstract][Full Text] [Related]
17. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
[TBL] [Abstract][Full Text] [Related]
18. High-grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging.
Lou S; Balluff B; de Graaff MA; Cleven AH; Briaire-de Bruijn I; Bovée JV; McDonnell LA
Proteomics; 2016 Jun; 16(11-12):1802-13. PubMed ID: 27174013
[TBL] [Abstract][Full Text] [Related]
19. Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma.
Roland CL; Boland GM; Demicco EG; Lusby K; Ingram D; May CD; Kivlin CM; Watson K; Al Sannaa GA; Wang WL; Ravi V; Pollock RE; Lev D; Cormier JN; Hunt KK; Feig BW; Lazar AJ; Torres KE
JAMA Surg; 2016 Apr; 151(4):347-54. PubMed ID: 26629783
[TBL] [Abstract][Full Text] [Related]
20. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma.
Ren B; Yu YP; Tseng GC; Wu C; Chen K; Rao UN; Nelson J; Michalopoulos GK; Luo JH
J Natl Cancer Inst; 2007 Jun; 99(11):868-80. PubMed ID: 17551147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
